Episode 69 | Kinevant is working on Namilumab - a potential new drug for sarcoidosis
Kinevant is working on a potential new drug to fight sarcoidosis. Namilumab is the working name for the drug, which -- if approved -- shows great promise in blocking the body's immune response to the causes of sarcoidosis.
In Episode 69 of the FSR Sarc Fighter Podcast, Kinevant CEO Bill Gerhart and Director of Patient Advocacy, Rayne Rogers discuss the status of namilumab, and how you as a sarcoidosis patient might want to participate in the stage 2 clinical trial.
Show Notes
- www.kinevant.com
- www.sarcoidosistrial.com
- ClinicalTrials.gov listing for RESOLVE-Lung: https://clinicaltrials.gov/ct2/show/NCT05314517
- ClinicalTrials.gov listing for RESOLVE-Heart: https://clinicaltrials.gov/ct2/show/NCT05351554